JP2016508134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508134A5 JP2016508134A5 JP2015549669A JP2015549669A JP2016508134A5 JP 2016508134 A5 JP2016508134 A5 JP 2016508134A5 JP 2015549669 A JP2015549669 A JP 2015549669A JP 2015549669 A JP2015549669 A JP 2015549669A JP 2016508134 A5 JP2016508134 A5 JP 2016508134A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000005721 HIV Infections Diseases 0.000 claims 4
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102000015084 HIV Reverse Transcriptase Human genes 0.000 claims 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 claims 1
- 102000033147 ERVK-25 Human genes 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- SOLUWJRYJLAZCX-LYOVBCGYSA-N OC1=C(C(N2[C@@H](C3)O[C@H]4C[C@@H]2CC4)=O)N3C=C(C(NCc(c(F)cc(F)c2)c2F)=O)C1=O Chemical compound OC1=C(C(N2[C@@H](C3)O[C@H]4C[C@@H]2CC4)=O)N3C=C(C(NCc(c(F)cc(F)c2)c2F)=O)C1=O SOLUWJRYJLAZCX-LYOVBCGYSA-N 0.000 description 1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745375P | 2012-12-21 | 2012-12-21 | |
US61/745,375 | 2012-12-21 | ||
US201361788397P | 2013-03-15 | 2013-03-15 | |
US61/788,397 | 2013-03-15 | ||
US201361845803P | 2013-07-12 | 2013-07-12 | |
US61/845,803 | 2013-07-12 | ||
PCT/US2013/076367 WO2014100323A1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016122743A Division JP6411409B2 (ja) | 2012-12-21 | 2016-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016508134A JP2016508134A (ja) | 2016-03-17 |
JP2016508134A5 true JP2016508134A5 (US20070167479A1-20070719-C00034.png) | 2016-08-12 |
JP6028105B2 JP6028105B2 (ja) | 2016-11-16 |
Family
ID=49917297
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015549669A Active JP6028105B2 (ja) | 2012-12-21 | 2013-12-19 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2016122743A Active JP6411409B2 (ja) | 2012-12-21 | 2016-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2018179844A Active JP6571256B2 (ja) | 2012-12-21 | 2018-09-26 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2019145317A Active JP6933690B2 (ja) | 2012-12-21 | 2019-08-07 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2021134172A Active JP7301918B2 (ja) | 2012-12-21 | 2021-08-19 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2023101636A Pending JP2023134483A (ja) | 2012-12-21 | 2023-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016122743A Active JP6411409B2 (ja) | 2012-12-21 | 2016-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2018179844A Active JP6571256B2 (ja) | 2012-12-21 | 2018-09-26 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2019145317A Active JP6933690B2 (ja) | 2012-12-21 | 2019-08-07 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2021134172A Active JP7301918B2 (ja) | 2012-12-21 | 2021-08-19 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
JP2023101636A Pending JP2023134483A (ja) | 2012-12-21 | 2023-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
Country Status (41)
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
DK3243826T3 (da) | 2012-04-26 | 2020-02-03 | Bristol Myers Squibb Co | Imidazothiadiazol-og imidazopyrazinderivater som proteaseaktiverede receptor 4- (par4) hæmmere til behandling af blodpladeaggregation |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
KR102527797B1 (ko) | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
NZ710079A (en) | 2013-01-15 | 2020-01-31 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
NO2865735T3 (US20070167479A1-20070719-C00034.png) * | 2013-07-12 | 2018-07-21 | ||
CA2916993C (en) * | 2013-07-12 | 2019-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
ZA201503540B (en) * | 2014-05-20 | 2016-10-26 | Cipla Ltd | Process for preparing polycyclic carbamoyl pyridone derivatives |
MD4820C1 (ro) | 2014-06-17 | 2023-03-31 | Pfizer Inc. | Compuşi dihidroizochinolinonici substituiţi |
NO2717902T3 (US20070167479A1-20070719-C00034.png) * | 2014-06-20 | 2018-06-23 | ||
TWI744723B (zh) * | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
EP3196201B1 (en) * | 2014-08-22 | 2021-04-28 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
TWI695003B (zh) * | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
AU2015371255B2 (en) | 2014-12-24 | 2018-09-27 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the treatment of HIV |
KR101960624B1 (ko) | 2014-12-24 | 2019-03-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 이소퀴놀린 화합물 |
TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
CN107108615B (zh) | 2015-03-04 | 2020-11-20 | 吉利德科学公司 | Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物 |
AU2016244035B2 (en) | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CA2984130C (en) * | 2015-04-28 | 2021-07-20 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and prodrug thereof |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
CA2999516A1 (en) | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of hiv |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
TWI737647B (zh) | 2015-11-09 | 2021-09-01 | 美商基利科學股份有限公司 | 用於治療人類免疫缺乏病毒之治療組合物 |
NZ743713A (en) | 2015-12-15 | 2020-01-31 | Gilead Sciences Inc | Human immunodeficiency virus neutralizing antibodies |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2018005328A1 (en) * | 2016-06-27 | 2018-01-04 | Concert Pharmaceuticals, Inc. | Deuterated bictegravir |
CA3021227C (en) | 2016-08-19 | 2020-11-03 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
US20180085387A1 (en) | 2016-09-27 | 2018-03-29 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
WO2018064080A1 (en) | 2016-09-28 | 2018-04-05 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
ES2881949T3 (es) | 2016-10-27 | 2021-11-30 | Gilead Sciences Inc | Forma cristalina de base libre de darunavir |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
CN108250215B (zh) * | 2016-12-28 | 2022-04-19 | 华创合成制药股份有限公司 | 一种新型抗hiv药物及其制备方法和用途 |
AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
CN106860464A (zh) * | 2017-02-16 | 2017-06-20 | 江苏艾迪药业有限公司 | 用于联合抗病毒治疗的药物组合物及应用 |
CN106860414B (zh) * | 2017-02-16 | 2019-12-24 | 江苏艾迪药业股份有限公司 | 一种用于抗hiv的复方制剂及其制备方法与应用 |
WO2018229798A1 (en) | 2017-06-13 | 2018-12-20 | Cipla Limited | Process for the preparation of bictegravir and intermediate thereof |
TWI728250B (zh) | 2017-06-21 | 2021-05-21 | 美商基利科學股份有限公司 | 靶向hiv gp120及cd3之多特異性抗體 |
PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
US20200171039A1 (en) | 2017-08-09 | 2020-06-04 | Viiv Healthcare Company | Combinations and uses and treatments |
JP2020529461A (ja) * | 2017-08-09 | 2020-10-08 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及び治療 |
TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
CA3078442A1 (en) * | 2017-10-06 | 2019-04-11 | Shionogi & Co., Ltd. | Stereoselective process for preparing substituted polycyclic pyridone derivatives |
JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
EP3700573A1 (en) | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP3740209A1 (en) * | 2018-01-19 | 2020-11-25 | Gilead Sciences, Inc. | Metabolites of bictegravir |
DK3749673T3 (da) | 2018-02-09 | 2022-06-20 | Sandoz Ag | Krystallinsk form af bictegravir-natrium |
KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
WO2019159199A1 (en) | 2018-02-16 | 2019-08-22 | Cipla Limited | Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof |
CA3090280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
CN109020911B (zh) * | 2018-04-16 | 2022-06-28 | 常州制药厂有限公司 | 用于制备bictegravir的中间体及其制备方法 |
US11466031B2 (en) | 2018-04-26 | 2022-10-11 | Mylan Laboratories Limited | Polymorphic forms of bictegravir and its sodium salt |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
CN110526930B (zh) * | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
CR20230571A (es) | 2018-05-31 | 2024-01-22 | Shionogi & Co | DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644) |
WO2019230857A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | 多環性ピリドン誘導体 |
EP3815689A4 (en) | 2018-06-27 | 2022-04-20 | National University Corporation Hokkaido University | ARENAVIRUS GROWTH INHIBITOR COMPRISING A POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE |
WO2020003151A1 (en) * | 2018-06-28 | 2020-01-02 | Honour Lab Limited | Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form |
CR20200653A (es) | 2018-07-03 | 2021-02-11 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y métodos de uso |
US11634431B2 (en) | 2018-07-12 | 2023-04-25 | Laurus Labs Limited | Process for purification of protected polycyclic carbamoylpyridone derivatives |
JP2021530523A (ja) | 2018-07-16 | 2021-11-11 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのカプシド阻害剤 |
TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
CN112996517A (zh) | 2018-09-19 | 2021-06-18 | 吉利德科学公司 | 预防hiv的整合酶抑制剂 |
EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
CN113226319B (zh) | 2018-10-22 | 2023-04-11 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
JP7460644B2 (ja) | 2018-10-31 | 2024-04-02 | ギリアード サイエンシーズ, インコーポレイテッド | Hpk1阻害剤としての置換6-アザベンゾイミダゾール化合物 |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
EP3653629A1 (en) | 2018-11-16 | 2020-05-20 | Sandoz AG | Acid addition salts of an integrase strand transfer inhibitor |
US20220144851A1 (en) | 2019-02-07 | 2022-05-12 | Cipla Limited | Novel polymorphs of integrase inhibitor |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
AU2020231115A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
EP4122537A1 (en) * | 2019-03-22 | 2023-01-25 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
US20200347036A1 (en) | 2019-04-17 | 2020-11-05 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
TWI762925B (zh) | 2019-05-21 | 2022-05-01 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
CN110229174A (zh) * | 2019-05-22 | 2019-09-13 | 博诺康源(北京)药业科技有限公司 | Bictegravir原料药基因毒性杂质的合成方法 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
CN110263404B (zh) * | 2019-06-12 | 2023-03-21 | 江苏大学 | 一种基于dpm模型的一体化预制泵站沉积特性的计算方法 |
CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
EP3993797A4 (en) * | 2019-06-18 | 2023-10-25 | Laurus Labs Limited | METHOD AND POLYMORPHOLIC FORMS OF BICTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS OR CO-CRYSTALS THEREOF |
US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN110698473B (zh) * | 2019-10-08 | 2020-12-18 | 浙江大学 | 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用 |
CN114727999A (zh) | 2019-11-26 | 2022-07-08 | 吉利德科学公司 | 用于预防hiv的衣壳抑制剂 |
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
JPWO2021107065A1 (US20070167479A1-20070719-C00034.png) * | 2019-11-28 | 2021-06-03 | ||
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US11697652B2 (en) | 2020-02-24 | 2023-07-11 | Gilead Sciences, Inc. | Tetracyclic compounds and uses thereof |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
CN113698420A (zh) * | 2020-05-22 | 2021-11-26 | 上海迪赛诺生物医药有限公司 | 比克替拉韦钠的新晶型及其制备方法 |
CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
TW202222798A (zh) | 2020-09-30 | 2022-06-16 | 美商基利科學股份有限公司 | 橋接三環胺甲醯基吡啶酮化合物及其用途 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN114426540B (zh) * | 2020-10-29 | 2024-04-26 | 上海拓界生物医药科技有限公司 | 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用 |
WO2022089562A1 (zh) * | 2020-10-30 | 2022-05-05 | 上海拓界生物医药科技有限公司 | 抑制基因缺陷的hiv病毒的用途 |
AU2021377614A1 (en) | 2020-11-11 | 2023-06-22 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
WO2022159387A1 (en) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023006087A1 (zh) * | 2021-07-30 | 2023-02-02 | 南京明德新药研发有限公司 | 大环吡啶酮类化合物及其应用 |
CN114230579A (zh) * | 2021-11-12 | 2022-03-25 | 南京艾迪医药科技有限公司 | 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物 |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
CN114605437A (zh) * | 2022-04-01 | 2022-06-10 | 遵义医科大学 | 连续一锅法制备三个替拉韦药物的合成工艺 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2023248240A1 (en) | 2022-06-21 | 2023-12-28 | Mylan Laboratories Limited | Polymorphic forms of bictegravir sodium |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024061257A1 (zh) * | 2022-09-20 | 2024-03-28 | 吉斯凯(苏州)制药有限公司 | 多环氮杂环酮类化合物及其应用 |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE788516A (fr) | 1971-09-10 | 1973-03-07 | Lonza Ag | Procede de fabrication d'esters alcoxyacetylacetiques |
GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
DE2658401A1 (de) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
US4575694A (en) | 1984-03-05 | 1986-03-11 | Allied Corporation | Coaxial connector |
DE3900736A1 (de) | 1989-01-12 | 1990-07-26 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches gemisch enthaltend einen mehrfunktionellen (alpha)-diazo-(beta)-ketoester, verfahren zu dessen herstellung und strahlungsempfindliches aufzeichnungsmaterial enthaltend dieses gemisch |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
DE4014649A1 (de) | 1990-05-08 | 1991-11-14 | Hoechst Ag | Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
JP2002529455A (ja) | 1998-11-09 | 2002-09-10 | ジェームズ・ブラック・ファウンデーション・リミテッド | ガストリンおよびコレシストキニン受容体リガンド類 |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
DE69939749D1 (de) | 1998-12-25 | 2008-11-27 | Shionogi & Co | Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften |
AU2001262732A1 (en) | 2000-06-14 | 2001-12-24 | Shionogi And Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
WO2002030426A1 (en) * | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
CN101513402B (zh) | 2001-08-10 | 2012-03-21 | 盐野义制药株式会社 | 抗病毒药 |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
IL160642A0 (en) | 2001-10-03 | 2004-07-25 | Ucb Sa | Pyrrolidinone derivatives |
BRPI0213522C1 (pt) | 2001-10-26 | 2021-05-25 | St Di Ricerche Di Biologia Molecolare P Angeletti S P A | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto |
US7109186B2 (en) | 2002-07-09 | 2006-09-19 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
AU2003267098B2 (en) | 2002-09-11 | 2008-11-20 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors |
EP4059923A1 (en) | 2002-11-20 | 2022-09-21 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
BRPI0507628A (pt) | 2004-02-11 | 2007-07-03 | Smithkline Beecham Corp | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto |
CN101014574A (zh) | 2004-03-09 | 2007-08-08 | 默克公司 | Hiv整合酶抑制剂 |
WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
EP1755586A2 (en) | 2004-04-29 | 2007-02-28 | The Regents of the University of California | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
WO2005110414A2 (en) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
CA2563601A1 (en) * | 2004-05-17 | 2005-11-24 | Tibotec Pharmaceuticals Ltd. | Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors |
US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
EP2229945A1 (en) | 2004-05-21 | 2010-09-22 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
JP2006118669A (ja) | 2004-10-25 | 2006-05-11 | Sanoh Industrial Co Ltd | 樹脂チューブ |
CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
EP1852434B1 (en) | 2005-02-21 | 2011-07-13 | Shionogi Co., Ltd. | Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity |
WO2006116764A1 (en) * | 2005-04-28 | 2006-11-02 | Smithkline Beecham Corporation | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP1888581A2 (en) | 2005-05-16 | 2008-02-20 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
CA2616314A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
CA2626956A1 (en) | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP2308490A1 (en) | 2005-12-30 | 2011-04-13 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
JP2009525261A (ja) | 2006-02-01 | 2009-07-09 | 日本たばこ産業株式会社 | レトロウイルス感染症の治療のための、6−(3−クロロ−2−フルオロベンジル)−1−[(2s)−1−ヒドロキシ−3−メチルブタン−2−イル]−7−メトキシ−4−オキソ−1,4−ジヒドロキノリン−3−カルボン酸またはその塩の使用 |
PL1992607T3 (pl) | 2006-03-06 | 2015-05-29 | Japan Tobacco Inc | Sposób wytwarzania związku 4-oksochinolinowego |
CN101437801B (zh) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2008010953A2 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
MX2009002689A (es) | 2006-09-12 | 2009-03-26 | Gilead Sciences Inc | Proceso e intermediarios para preparar inhibidores de integrasa. |
EP2084160A1 (en) | 2006-10-18 | 2009-08-05 | Merck & Co., Inc. | Hiv integrase inhibitors |
ES2603617T3 (es) | 2007-02-23 | 2017-02-28 | Gilead Sciences, Inc. | Moduladores de propiedades farmacocinéticas de la terapéutica |
US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
WO2009006203A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
CN103480000A (zh) | 2007-06-29 | 2014-01-01 | 吉里德科学公司 | 治疗用组合物和方法 |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
WO2009018350A1 (en) | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Pyrone analog compositions and methods |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
GB0803019D0 (en) | 2008-02-19 | 2008-03-26 | Btg Int Ltd | Fluorinated compounds |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
EP2320909B8 (en) | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Chemical compounds |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
PT2320908E (pt) | 2008-07-25 | 2014-03-06 | Shionogi & Co | Pró-fármacos de dolutegravir |
WO2010011816A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011818A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
ES2964383T3 (es) | 2008-12-11 | 2024-04-05 | Viiv Healthcare Co | Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona |
MX2011006241A (es) | 2008-12-11 | 2011-06-28 | Shionogi & Co | Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios. |
EP2367821B1 (en) | 2008-12-17 | 2015-09-16 | Merck Patent GmbH | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
AP3250A (en) | 2009-02-06 | 2015-05-31 | Gilead Sciences Inc | Tablets for combination therapy |
TWI518084B (zh) * | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
PT2444400T (pt) | 2009-06-15 | 2018-06-06 | Shionogi & Co | Derivado de carbamoilpiridona policíclico substituído |
KR101280198B1 (ko) | 2009-09-02 | 2013-06-28 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
ES2688925T3 (es) | 2010-01-27 | 2018-11-07 | Viiv Healthcare Company | Tratamiento antiviral |
WO2011105590A1 (ja) | 2010-02-26 | 2011-09-01 | 日本たばこ産業株式会社 | 1,3,4,8-テトラヒドロ-2H-ピリド[1,2-a]ピラジン誘導体及びそのHIVインテグラーゼ阻害剤としての利用 |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体 |
EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
CN106083891B (zh) | 2010-08-05 | 2018-03-23 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的化合物的制造方法 |
SI2620436T1 (en) | 2010-09-24 | 2018-08-31 | Shionogi & Co., Ltd. | A prodrug substituted polycyclic carbamoyl pyridone derivative |
KR101923103B1 (ko) | 2010-11-19 | 2018-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물 |
WO2012106534A2 (en) | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
AP2015008931A0 (en) | 2011-04-21 | 2015-12-31 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
US9121496B2 (en) | 2011-06-29 | 2015-09-01 | Arvinmeritor Technology, Llc | Drive axle system and a method of control |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
RS56667B1 (sr) | 2011-07-07 | 2018-03-30 | Janssen Sciences Ireland Uc | Kombinovane formulacije darunavira |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
US9206197B2 (en) | 2011-09-14 | 2015-12-08 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
WO2013087581A1 (en) | 2011-12-12 | 2013-06-20 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
WO2014014933A1 (en) | 2012-07-20 | 2014-01-23 | Merck Sharp & Dohme Corp. | Hiv treatment with amido-substituted pyrimidinone derivatives |
EP2877469A4 (en) | 2012-07-25 | 2016-04-06 | Merck Sharp & Dohme | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE |
US8877931B2 (en) | 2012-08-03 | 2014-11-04 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
WO2014074675A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
JP2016503030A (ja) | 2012-12-14 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 医薬組成物 |
WO2014099586A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR102527797B1 (ko) | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
EP2934482A4 (en) | 2012-12-21 | 2016-07-20 | Merck Sharp & Dohme | ADMINISTRATIVE FORMULATIONS |
US20140221380A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
US9493479B2 (en) | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
CA2916993C (en) * | 2013-07-12 | 2019-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
NO2865735T3 (US20070167479A1-20070719-C00034.png) | 2013-07-12 | 2018-07-21 | ||
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
EA030695B1 (ru) | 2013-09-27 | 2018-09-28 | Мерк Шарп И Доум Корп. | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
EP3096763B1 (en) | 2014-01-21 | 2019-12-25 | Laurus Labs Limited | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
WO2015138933A1 (en) | 2014-03-13 | 2015-09-17 | Assia Chemical Industries Ltd. | Solid state forms of dolutegravir sodium |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
NO2717902T3 (US20070167479A1-20070719-C00034.png) | 2014-06-20 | 2018-06-23 | ||
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TWI733652B (zh) * | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
AU2016244035B2 (en) | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
SI4070787T1 (sl) | 2015-06-30 | 2023-07-31 | Gilead Sciences, Inc. | Farmacevtske formulacije |
CA2921336A1 (en) | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
TWI737647B (zh) | 2015-11-09 | 2021-09-01 | 美商基利科學股份有限公司 | 用於治療人類免疫缺乏病毒之治療組合物 |
-
2013
- 2013-12-19 KR KR1020227018650A patent/KR102527797B1/ko active IP Right Grant
- 2013-12-19 MX MX2015008009A patent/MX344879B/es active IP Right Grant
- 2013-12-19 PT PT138159371T patent/PT2822954E/pt unknown
- 2013-12-19 CA CA3012242A patent/CA3012242C/en active Active
- 2013-12-19 MY MYPI2015001580A patent/MY164352A/en unknown
- 2013-12-19 UA UAA201612380A patent/UA123572C2/uk unknown
- 2013-12-19 RS RS20160407A patent/RS54873B1/sr unknown
- 2013-12-19 EP EP13815937.1A patent/EP2822954B1/en active Active
- 2013-12-19 BR BR112015014714-3A patent/BR112015014714B1/pt active IP Right Grant
- 2013-12-19 CR CR20170279A patent/CR20170279A/es unknown
- 2013-12-19 US US14/133,858 patent/US9216996B2/en active Active
- 2013-12-19 TW TW107127529A patent/TWI693224B/zh active
- 2013-12-19 KR KR1020237014240A patent/KR20230061576A/ko not_active Application Discontinuation
- 2013-12-19 NZ NZ709260A patent/NZ709260A/en unknown
- 2013-12-19 EP EP15201519.4A patent/EP3067358B1/en active Active
- 2013-12-19 UA UAA201506209A patent/UA114351C2/uk unknown
- 2013-12-19 AR ARP130104930A patent/AR094197A1/es active IP Right Grant
- 2013-12-19 LT LT15201519T patent/LT3067358T/lt unknown
- 2013-12-19 ES ES15201519T patent/ES2753548T3/es active Active
- 2013-12-19 CA CA2893843A patent/CA2893843C/en active Active
- 2013-12-19 PL PL15201519T patent/PL3067358T3/pl unknown
- 2013-12-19 KR KR1020227001078A patent/KR102406288B1/ko active IP Right Grant
- 2013-12-19 KR KR1020157019194A patent/KR101770048B1/ko active IP Right Grant
- 2013-12-19 JP JP2015549669A patent/JP6028105B2/ja active Active
- 2013-12-19 NZ NZ718708A patent/NZ718708A/en unknown
- 2013-12-19 ES ES19185121T patent/ES2926068T3/es active Active
- 2013-12-19 CN CN202010188107.9A patent/CN111303152B/zh active Active
- 2013-12-19 SG SG11201504857SA patent/SG11201504857SA/en unknown
- 2013-12-19 EA EA201890236A patent/EA037633B1/ru unknown
- 2013-12-19 LT LTEP19185121.1T patent/LT3608325T/lt unknown
- 2013-12-19 MD MDA20170067A patent/MD4754C1/ro active IP Right Grant
- 2013-12-19 PE PE2016000694A patent/PE20170528A1/es unknown
- 2013-12-19 KR KR1020197031864A patent/KR102120875B1/ko active IP Right Grant
- 2013-12-19 KR KR1020207015960A patent/KR102246963B1/ko active IP Right Grant
- 2013-12-19 HU HUE15201519A patent/HUE046559T2/hu unknown
- 2013-12-19 HU HUE19185121A patent/HUE059688T2/hu unknown
- 2013-12-19 TW TW102147242A patent/TWI642669B/zh active
- 2013-12-19 MY MYPI2016001880A patent/MY191741A/en unknown
- 2013-12-19 BR BR122015029881-4A patent/BR122015029881B1/pt active IP Right Grant
- 2013-12-19 ME MEP-2016-93A patent/ME02400B/me unknown
- 2013-12-19 MD MDA20200093A patent/MD4841B1/ro not_active IP Right Cessation
- 2013-12-19 UY UY35213A patent/UY35213A/es not_active Application Discontinuation
- 2013-12-19 PT PT191851211T patent/PT3608325T/pt unknown
- 2013-12-19 CN CN201711080644.6A patent/CN107674086B/zh active Active
- 2013-12-19 KR KR1020177016697A patent/KR102040007B1/ko active IP Right Grant
- 2013-12-19 DK DK15201519T patent/DK3067358T3/da active
- 2013-12-19 EA EA201591027A patent/EA030003B1/ru active Protection Beyond IP Right Term
- 2013-12-19 CN CN201380073134.XA patent/CN104995198B/zh active Active
- 2013-12-19 WO PCT/US2013/076367 patent/WO2014100323A1/en active Application Filing
- 2013-12-19 HU HUE13815937A patent/HUE028284T2/en unknown
- 2013-12-19 PL PL19185121.1T patent/PL3608325T3/pl unknown
- 2013-12-19 MX MX2017000362A patent/MX357940B/es unknown
- 2013-12-19 PL PL13815937.1T patent/PL2822954T3/pl unknown
- 2013-12-19 AU AU2013361401A patent/AU2013361401C1/en active Active
- 2013-12-19 SI SI201330197A patent/SI2822954T1/sl unknown
- 2013-12-19 PT PT152015194T patent/PT3067358T/pt unknown
- 2013-12-19 CA CA3131094A patent/CA3131094A1/en active Pending
- 2013-12-19 MD MDA20150064A patent/MD4736C1/ro active IP Right Grant
- 2013-12-19 TW TW112109785A patent/TWI830624B/zh active
- 2013-12-19 PH PH12019501848A patent/PH12019501848A1/en unknown
- 2013-12-19 ES ES13815937.1T patent/ES2577283T3/es active Active
- 2013-12-19 SI SI201332004T patent/SI3608325T1/sl unknown
- 2013-12-19 DK DK19185121.1T patent/DK3608325T3/da active
- 2013-12-19 AP AP2015008510A patent/AP2015008510A0/xx unknown
- 2013-12-19 TW TW109111537A patent/TWI752457B/zh active
- 2013-12-19 CN CN202310322212.0A patent/CN116640140A/zh active Pending
- 2013-12-19 PE PE2015001036A patent/PE20151499A1/es active IP Right Grant
- 2013-12-19 HR HRP20220899TT patent/HRP20220899T1/hr unknown
- 2013-12-19 TW TW110146626A patent/TWI815245B/zh active
- 2013-12-19 DK DK13815937.1T patent/DK2822954T3/en active
- 2013-12-19 EP EP22178867.2A patent/EP4122935A1/en active Pending
- 2013-12-19 SI SI201331609T patent/SI3067358T1/sl unknown
- 2013-12-19 EP EP19185121.1A patent/EP3608325B1/en active Active
- 2013-12-19 KR KR1020217012463A patent/KR102351912B1/ko active IP Right Grant
-
2015
- 2015-06-10 IL IL239316A patent/IL239316A/en active IP Right Grant
- 2015-06-18 MX MX2022013596A patent/MX2022013596A/es unknown
- 2015-06-18 CL CL2015001756A patent/CL2015001756A1/es unknown
- 2015-06-18 MX MX2020003055A patent/MX2020003055A/es unknown
- 2015-06-22 PH PH12015501445A patent/PH12015501445B1/en unknown
- 2015-06-22 HK HK15105909.2A patent/HK1205124A1/xx unknown
- 2015-07-17 CR CR20150380A patent/CR20150380A/es unknown
- 2015-07-31 US US14/815,504 patent/US9663528B2/en active Active
- 2015-10-26 ZA ZA2015/07997A patent/ZA201507997B/en unknown
-
2016
- 2016-02-29 PH PH12016500389A patent/PH12016500389B1/en unknown
- 2016-04-11 CL CL2016000837A patent/CL2016000837A1/es unknown
- 2016-04-21 HK HK16104629.3A patent/HK1216643A1/zh unknown
- 2016-04-21 HK HK18110106.0A patent/HK1250711A1/zh unknown
- 2016-05-20 HR HRP20160544TT patent/HRP20160544T1/hr unknown
- 2016-05-23 IL IL245780A patent/IL245780B/en active IP Right Grant
- 2016-05-30 CY CY20161100472T patent/CY1117570T1/el unknown
- 2016-06-01 SM SM201600157T patent/SMT201600157B/it unknown
- 2016-06-21 JP JP2016122743A patent/JP6411409B2/ja active Active
- 2016-08-17 IL IL247311A patent/IL247311A0/en unknown
- 2016-11-11 US US15/349,934 patent/US9732092B2/en active Active
- 2016-11-24 AU AU2016262722A patent/AU2016262722B2/en active Active
-
2017
- 2017-05-11 CL CL2017001191A patent/CL2017001191A1/es unknown
- 2017-05-18 US US15/599,151 patent/US10035809B2/en active Active
-
2018
- 2018-06-25 US US16/017,371 patent/US10689399B2/en active Active
- 2018-08-17 LU LU00083C patent/LUC00083I2/en unknown
- 2018-08-21 LT LTPA2018511C patent/LTC2822954I2/lt unknown
- 2018-08-22 NL NL300947C patent/NL300947I2/nl unknown
- 2018-08-23 HU HUS1800035C patent/HUS1800035I1/hu unknown
- 2018-08-23 CY CY2018022C patent/CY2018022I2/el unknown
- 2018-09-19 AU AU2018232957A patent/AU2018232957B2/en active Active
- 2018-09-26 JP JP2018179844A patent/JP6571256B2/ja active Active
-
2019
- 2019-02-22 ZA ZA2019/03516A patent/ZA201903516B/en unknown
- 2019-08-07 JP JP2019145317A patent/JP6933690B2/ja active Active
- 2019-10-29 HR HRP20191957TT patent/HRP20191957T1/hr unknown
- 2019-11-05 CY CY20191101151T patent/CY1122246T1/el unknown
-
2020
- 2020-05-01 AU AU2020202914A patent/AU2020202914B2/en active Active
- 2020-05-06 US US16/868,119 patent/US11548901B2/en active Active
- 2020-05-28 IL IL274988A patent/IL274988A/en unknown
-
2021
- 2021-08-19 JP JP2021134172A patent/JP7301918B2/ja active Active
- 2021-08-23 AU AU2021221427A patent/AU2021221427B2/en active Active
-
2023
- 2023-06-21 JP JP2023101636A patent/JP2023134483A/ja active Pending
- 2023-12-30 AU AU2023286038A patent/AU2023286038A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016508134A5 (US20070167479A1-20070719-C00034.png) | ||
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
JP2016515561A5 (US20070167479A1-20070719-C00034.png) | ||
JP2016518337A5 (US20070167479A1-20070719-C00034.png) | ||
NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
JP2016527217A5 (US20070167479A1-20070719-C00034.png) | ||
NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
JP2016034978A5 (US20070167479A1-20070719-C00034.png) | ||
PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
JP2013518107A5 (US20070167479A1-20070719-C00034.png) | ||
SI2932970T1 (en) | Antiviral therapy | |
IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
NZ741957A (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
EA201391108A1 (ru) | Лечение липодистрофии | |
MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
WO2015148415A3 (en) | Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease | |
JP2015516419A5 (US20070167479A1-20070719-C00034.png) | ||
JP2015532296A5 (US20070167479A1-20070719-C00034.png) | ||
JP2015522018A5 (US20070167479A1-20070719-C00034.png) | ||
MX2021002321A (es) | Nuevos metodos. | |
HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
JP2014148552A5 (US20070167479A1-20070719-C00034.png) |